Plumbagin inhibits prostate carcinogenesis in intact and castrated PTEN knockout mice via targeting PKCε, Stat3, and epithelial-to-mesenchymal transition markers

Cancer Prevention Research

Volumn 8, Issue 5, 2015, Pages 375-386

  Hafeez, Bilal Bin ^a   Fischer, Joseph W ^a   Singh, Ashok ^a   Zhong, Weixiong ^a   Mustafa, Ala ^a   Meske, Louise ^a   Sheikhani, Mohammad Ozair ^a   Verma, Ajit Kumar ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; NAPHTHOQUINONE; PLUMBAGIN; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; STAT3 PROTEIN; TRANSCRIPTION FACTOR SLUG; VIMENTIN; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOGENESIS; PROTEIN EXPRESSION; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CARCINOGENESIS; DRUG EFFECTS; GENETICS; METABOLISM; ORCHIECTOMY; PATHOLOGY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOMARKERS; CARCINOGENESIS; EPITHELIAL-MESENCHYMAL TRANSITION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NAPHTHOQUINONES; ORCHIECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEIN KINASE C-EPSILON; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84942522244     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0231     Document Type: Article

References (59)

1. Society AC. Cancer facts and figures 2014. Atlanta, GA: American Cancer Society; 2014.
2. Albertsen P. Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer 2008;112:1-3.
3. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23:1-9.
4. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000;21:179-82.
5. Kim H, Hall P, Smith M, Kirk M, Prasain JK, Barnes S, et al. Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. J Nutr 2004;134:3445S-3452S.
6. Adhami VM, Siddiqui IA, Syed DN, Lall RK, Mukhtar H. Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis 2012;33:644-51.
7. Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, Resnick MI, et al. Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res 2007;67:6925-35.
8. Sandur SK, Ichikawa H, Sethi G, Ahn KS, Aggarwal BB. Plumbagin (5-hydroxy-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and lkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 2006;281:17023-33.
9. Padhye S, Dandawate P, Yusufi M, Ahmad A, Sarkar FH. Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev 2012;32:1131-58.
10. Son TG, Camandola S, Arumugam TV, Cutler RG, Telljohann RS, Mughal MR, et al. Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. J Neurochem 2010;112:1316-26.
11. Sugie S, Okamoto K, Rahman KM, Tanaka T, Kawai K, Yamahara J, et al. Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett 1998;127:177-83.
12. Kuo PL, Hsu YL, Cho CY. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 2006;5:3209-21.
13. Hsu YL, Cho CY, Kuo PL, Huang YT, Lin CC. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther 2006;318:484-94.
14. Wang CC, Chiang YM, Sung SC. Hsu YL, Chang JK, Kuo PL. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett 2008;259:82-98.
15. Sung B, Oyajobi B, Aggarwal BB. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther 2012;11:350-59.
16. Yan W, Wang TY, Fan QM, Du L, Xu JK, Zhai ZJ, et al. Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice. Acta Pharmacol Sin 2014;35:124-34.
17. Sand JM, Bin Hafeez B, Jamal MS, Witkowsky O, Siebers EM, Fischer J, et al. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas. Carcinogenesis 2012;33:184-90.
18. Chen CA, Chang HH, Kao CY, Tsai TH, Chen YJ. Plumbagin, isolated from Plumbago zeylanica, induces cell death through apoptosis in human pancreatic cancer cells. Pancreatology 2009;9:797-809.
19. Hafeez BB, Jamal MS, Fischer JW, Mustafa A, Verma AK. Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways. Int J Cancer 2012;131:2175-86.
20. Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res 2008;68:9024-32.
21. Hafeez BB, Zhong W, Fischer JW, Mustafa A, Shi X, Meske L, et al. Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model. Mol Oncol 2013;7:428-39.
22. Hafeez BB, Zhong W, Mustafa A, Fischer JW, Witkowsky O, Verma AK. Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCε, Stat3 and neuroendocrine markers. Carcinogenesis 2012;33:2586-92.
23. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-21.
24. Grudzinski JJ, Floberg JM, Mudd SR, Jeffery JJ, Peterson ET, Nomura A, et al. Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT. Phys Med Biol 2012;57:1641-57.
25. Hafeez BB, Zhong W, Weichert J, Dreckschmidt NE, Jamal MS, Verma AK. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res 2011;71:2318-27.
26. Hsieh Y, Chew Lin L, Tsai T. Measurement and pharmacokinetic study of plumbagin in a conscious freely moving rat using liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006;844:1-5.
27. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
28. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
29. Martínez-Gimeno C, Díaz-Meco MT, Domínguez I, Moscat J. Alterations in levels of different protein kinase C isotypes and their influence on behavior of squamous cell carcinoma of the oral cavity: epsilon PKC, a novel prognostic factor for relapse and survival. Head Neck 1995;17:516-25.
30. Aziz MH, Manoharan HT, Church DR, Dreckschmidt NE, Zhong W, Oberley TD, et al. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res 2007;67:8828-38.
31. Aziz MH, Hafeez BB, Sand JM, Pierce DB, Aziz SW, Dreckschmidt NE, et al. Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 2010;29:3100-9.
32. Koren R, Ben Meir D, Langzam L, Dekel Y, Konichezky M, Baniel J, et al. Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol Rep 2004;11:321-26.
33. Benavides F, Blando J, Perez CJ, Garg R, Conti CJ, DiGiovanni J, et al. Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions. Cell Cycle 2011;10:268-77.
34. Aziz MH, Manoharan HT, Verma AK. Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res 2007;67:1385-94.
35. Sugie S, Tsukino H, Mukai S, Akioka T, Shibata N, Nagano M, et al. Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men. Tumour Biol 2014;35:2717-21.
36. Garcia M, Velez R, Romagosa C, Majem B, Pedrola N, Rigau M, et al. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int 2014;113:E164-77.
37. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, et al. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002;52:253-63.
38. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003;63:2306-11.
39. Wu M, Bai X, Xu G, Wei J, Zhu T, Zhang Y, et al. Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression. Proteomics 2007;7:1973-83.
40. Sethi S, Macoska J, Chen W, Sarkar FH. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 2010;3:90-99.
41. Abedinpour P, Baron VT, Chrastina A, Welsh J, Borgström P. The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo. Prostate 2013;73:489-99.
42. Parimala R, Sachdanandam P. Effect of plumbagin on some glucose metabolising enzymes studied in rats in experimental hepatoma. Mol Cell Biochem 1993;125:59-63.
43. Azad Chowdhury AK, Sushanta KC, Azad Khan AK. Antifertility activity of Plumbago zeylanica Linn. root. Indian J Med Res 1982;76:99-101.
44. Bhargava SK. Effect of testosterone replacement therapy on quantitative spermatogenesis following plumbagin treatment in immature rats. Acta Eur Fertil 1986;17:217-19.
45. Wu D, Foreman TL, Gregory CW, McJilton MA, Wescott GG, Ford OH, et al. Protein kinase C epsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002;62:2423-29.
46. Meshki J, Caino MC, von Burstin VA, Griner E, Kazanietz MG. Regulation of prostate cancer cell survival by protein kinase Cepsilon involves bad phosphorylation and modulation of the TNFalpha/JNK pathway. J Biol Chem 2010;285:26033-40.
47. Wu D, Thakore CU, Wescott GG, McCubrey JA, Terrian DM. Integrin signaling links protein kinase C epsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene 2004;23:8659-72.
48. McJilton MA, Van Sikes C, Wescott GG. Protein kinase C epsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 2003;22:7958-68.
49. Garg R, Blando J, Perez CJ, Wang H, Benavides FJ, Kazanietz MG. Activation of nuclear factor κB (NF-κB) in prostate cancer is mediated by protein kinase C epsilon (PKCepsilon). J Biol Chem 2012;287:37570-82.
50. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 2012;72:4883-89.
51. Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 2012;360:52-58.
52. Azevedo A, Cunha V, Teixeira AL, Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2011;2:384-96.
53. Kutikov A, Makhov P, Golovine K, Canter DJ, Sirohi M, Street R, et al. Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. Urology 2011;78:.e7-11.
54. Terracciano D, Bruzzese D, Ferro M, Autorino R, di Lorenzo G, Buonerba C, et al. Soluble interleukin-6 receptor to interleukin-6 (sIL - 6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy. Oncol Lett 2011;2:861-64.
55. Ivaska J, Vuoriluoto K, Huovinen T, Izawa I, Inagaki M, Parker PJ. PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J 2005;24:3834-45.
56. Alves CC, Carneiro F, Hoefler H, Becker KF. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci 2009;14:3035-50.
57. Camp ER, Findlay VJ, Vaena SG, Walsh J, Lewin DN, Turner DP, et al. Slug expression enhances tumor formation in a noninvasive rectal cancer model. J Surg Res 2011;170:56-63.
58. Emadi Baygi M, Soheili ZS, Essmann F, Deezagi A, Engers R, et al. Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biol 2010;31:297-307
59. Wu K, Gore C, Yang L, Fazli L, Gleave M, Pong RC, et al. Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Mol Endocrinol 2012;26:1496-507.